Yuanxin Medical Completes Over RMB 200 Million Series B Strategic Financing to Advance Iron-Based Bioresorbable Stent Platforms

VCBeat learned that recently, Biotyx Medical (Shenzhen) Co., Ltd. ("Biotyx Medical") has successfully completed a strategic B-round financing of over 200 million yuan. This round of financing introduced several strategic investors, including Gongqingcheng Huayi Private Equity Fund Management Co., Ltd. and Guangfa Qianhe Investment Co., Ltd. The A-round investors, IDG Capital and Shanghai Baoquan, continued to follow up on their investments. The B-round capital increase agreement and shareholder agreement have now been signed. Investors in this round of financing will invest more than 200 million yuan into Biotyx Medical according to the terms of the capital increase agreement.

Biotyx Medical's iron-based bioabsorbable materials platform has undergone 17 years of steady development, positioning it as an innovator and leader in the global bioabsorbable stent field. The recent acquisition of Series B strategic financing marks another significant milestone for Biotyx Medical’s development, providing essential financial support for its future growth. This funding will further effectively incentivize the iron-based bioabsorbable project team, attract external talent, and accelerate the clinical and regulatory approval processes for the project. Biotyx Medical will utilize the funds efficiently, actively integrate internal and external resources, while further diversifying its existing product portfolio to promote comprehensive and sustainable business growth, delivering groundbreaking clinical treatment solutions for patients worldwide.

At the same time, this round of financing has advanced Biotyx Medical's process of independent financing operations in the capital market. The expansion of a leading team of strategic investors will better support Biotyx Medical’s subsequent capitalization efforts, thereby enhancing the overall value of Biotyx Medical.

Biotyx Medical is the only company in the world engaged in the research and development of iron-based bioresorbable stents, possessing advanced scientific research conditions and a high-level R&D team. It is committed to developing innovative interventional medical device products to serve a wide range of patients and address unmet clinical needs globally. Biotyx Medical's globally pioneering iron-based bioresorbable material platform has broad application and expansion potential in the medical field. Currently, it has successfully developed several fully degradable iron-based bioresorbable stent products, which are applied in multiple mainstream areas such as coronary heart disease, pediatric pulmonary artery stenosis, and infrapopliteal artery stenosis.

• Three core products are at different stages of clinical trials and market access, all of which have been approved to enter the special review process for innovative medical devices at the national level. The absorbable drug-eluting coronary stent has completed patient enrollment for Phase III clinical trials in China, with over 1,300 implants in the third phase, and the EU CE application has been submitted.

• Biotyx Medical's iron-based bioresorbable vascular scaffold for children has received FDA Compassionate Use approval in the United States, registration certification in Malaysia, and the EU CE mark, gaining market access qualifications.

• Bioabsorbable drug-eluting peripheral stent receives U.S. FDA compassionate use approval and ethical approval from multiple centers in Europe, with the first case successfully completed in Florence, Italy in July this year.

All tasks are proceeding smoothly and will bring significant breakthroughs in the effective treatment of related diseases.

Related Recommendations:"Global First! Biotyx Medical Competes in the Billion-Dollar Stent Market with Iron-Based Bioabsorbable Vascular Stents"